I'm not a cancer biologist but I work in the field of supporting cancer research and targeted therapy. My naive take is: the type of mutation and its effect on

I'm not a cancer biologist but I work in the field of supporting cancer research and targeted therapy. My naive take is: the type of mutation and its effect on cancer progression is still being studied heavily. A lot of the understanding of biological pathways and functional impacts of these mutations are being updated and very conservatively corrected. From a systems biology point of view, the whole body is so mechanistically complex in its response to environmental and internal stress that it's a bit difficult to predict outcome / prognosis. Important cancer pathways are well studied and are usually involved in disease progression but it is still very tissue type / biomarker categorisation specific. The real driver mutations are being discovered for each cancer type but the ultimate goal is be able to see the big picture.